GP Farmasi Indonesia hold its national congress on 23-25 October 2015 at Trans Luxury Hotel, Bandung with its topic “New Paradigm in the Process of Developing Autonomy Pharmaceutical Business as Nawa Cita (National Priority Agenda)”. Imedco was represented by Suryanto, Audrey Clarissa, and Purwadi Dwijodarmanto.
During the meeting, it was highlighted that Pharmaceutical industry is one of the government priorities as directed by President Jokowi. Therefore, development in pharmaceutical industries will be fully supported by the government. In line with it, pharmaceutical industries and other pharmaceutical businesses should be ready to support the universal health coverage, even though it has its own challenges esp. in pricing. The industrial commission of GP Farmasi Indonesia encourages pharmaceutical industries to play in the “same level playing field”.
In this XV national congress, Mr. F. Tirto Kusnadi was elected as the new Chairperson of GP Farmasi Indonesia 2016-2021. Congratulations to Mr. Tirto in fostering the development of pharmaceutical companies in Indonesia.
Imedco Djaja had been audited by NAFDC
In November 2015, Imedco Djaja has completed its total renovation and added new facilities that had taken place since October 2014. Now, Imedco has production facilities for solid, liquid and semisolid products. It is also supported with key facilities such as HVAC and Purified Water System according to the prevailing requirements. These critical facilities are as important as the whole facility inside the production plant; without any of these it is impossible to produce high quality products.
This facility came about as a result of Imedco’s commitment to invest in the country’s infrastructure by modernizing the national pharmaceutical industry and comply with the current national and international regulations. This facility will allow Imedco to meet the growth of local and regional demands for medicines. This in turn, positions Imedco to successfully compete within a new, globalized scenario by fulfilling strong international commitments.
As soon as the renovation and addition of facility has finished, Imedco requested a Good Manufacturing Practices (GMP) audit to the National Agency of Food, Drug, and Cosmetics (NAFDC). The audit took place in the end of November 2015 and we are now progressing for the final review. We will soon be awarded a certificate of Compliance with GMP so that Imedco may start to contribute to the Indonesian healthcare system.
Patient is our FOCUS and they are the fundamental reason in our products development. In Imedco, understanding the patients’ needs drive us to create new ideas, new inventions and new ways of thinking.
Along with the scientific development, we strive to yield innovative rare and specialty medicine with strong added value for our patients.
As to this moment, we have developed not only conventional products with added values, but also we have started to develop innovative approaches drugs such as New Drug Delivery System (NDDS).
Our strength in developing these products lies on 2 matters. First, it is Human Resource. Our RND team consists of competent people in their fields. They have strong passion in what they do, as well as high fighting spirit to find and create new products that may fulfill the needs of many patients.
Second, it is the commitment of the company. This clear direction from the top management energizes our RND team to reach their fullest abilities in developing beneficial products which demonstrates our continued commitment to patients and their caregivers.